TJ-111

N/A

Report date: 2025/07/30 10:29:04

Base Information

Drug NameTJ-111
Drug Alias NameTJ-111TJ111
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitorsTubulin inhibitorsAnti-Trop-2 +[4] 
TargetsDNA topoisomerase ITubulinTumor-associated calcium signal transducer 2 +[4] 
Therapy Area/IndicationsCarcinoma, Transitional Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesPhrontline Biopharma Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPhrontline Biopharma Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Transitional Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A